Header Logo

Karthikeyan Ramasamy

TitlePostdoc Fellows and Associates
InstitutionBaylor College of Medicine
DepartmentPostDoc
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Al-Kaisi F, Gudger A, Ngu L, Poynton M, Lam HPJ, Morgan L, Yang L, Young J, Walker M, Tsagkaraki I, Anderson L, Chauhan SR, Maddams R, Soutar R, Triantafillou M, Prideaux S, Obeidalla A, Eyre TA, Bygrave C, Kothari J, Basu S, Ramasamy K. Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients. Br J Haematol. 2023 04; 201(1):162-167. PMID: 36720464.
      Citations:    Fields:    Translation:Humans
    2. Kikuchi H, Amofa E, Mcenery M, Schey SA, Ramasamy K, Farzaneh F, Calle Y. Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics. Cancers (Basel). 2023 Jan 11; 15(2). PMID: 36672411.
      Citations:    
    3. Yong K, Wilson W, de Tute RM, Camilleri M, Ramasamy K, Streetly M, Sive J, Bygrave CA, Benjamin R, Chapman M, Chavda SJ, Phillips EH, Del Mar Cuadrado M, Pang G, Jenner R, Dadaga T, Kamora S, Cavenagh J, Clifton-Hadley L, Owen RG, Popat R. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. Lancet Haematol. 2023 Feb; 10(2):e93-e106. PMID: 36529145.
      Citations: 2     Fields:    Translation:HumansAnimalsCTClinical Trials
    4. Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Firas AK, Gudger A, Ngu L, Poynton M, Lam HPJ, Morgan L, Yang L, Young J, Walker M, Tsagkaraki I, Anderson L, Chauhan SR, Maddams R, Soutar R, Triantafillou M, Prideaux S, Obeidalla A, Eyre TA, Bygrave C, Basu S, Ramasamy K. Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study. Hematology. 2022 Dec; 27(1):691-699. PMID: 35666686.
      Citations:    
    5. Djebbari F, Poynton M, Sangha G, Anderson L, Maddams R, Eyre TA, Vallance G, Basu S, Ramasamy K. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series. Hematology. 2022 Dec; 27(1):204-207. PMID: 35134321.
      Citations:    
    6. Ramasamy K, Iqbal G, Brouwer R, Stalker V, Akhtar S, Varghese S, Lindsay J, Schey S, Drayson M, Dunn J. Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial. Blood Cancer J. 2022 11 29; 12(11):162. PMID: 36446771; PMCID: PMC9708638.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    7. Lee HC, Ramasamy K, Weisel K, Abonour R, Hardin JW, Rifkin RM, Ailawadhi S, Terebelo HR, Durie BGM, Tang D, Joshi P, Liu L, Jou YM, Che M, Hernandez G, Narang M, Toomey K, Gasparetto C, Wagner LI, Jagannath S. Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry. Clin Lymphoma Myeloma Leuk. 2023 02; 23(2):112-122. PMID: 36567211.
      Citations: 1     Fields:    Translation:Humans
    8. Richardson PG, Mateos MV, Vangsted AJ, Ramasamy K, Abildgaard N, Ho PJ, Quach H, Bahlis NJ. The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease. Expert Rev Proteomics. 2022 Apr-Jun; 19(4-6):235-246. PMID: 36342226.
      Citations: 1     Fields:    Translation:HumansCells
    9. Maouche N, Kishore B, Bhatti Z, Basu S, Karim F, Sundararaman S, Collings F, Tseu B, Leary H, Ryman N, Reddy U, Vallance GD, Kothari J, Ramasamy K. Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort. PLoS One. 2022; 17(7):e0270854. PMID: 35797277; PMCID: PMC9262230.
      Citations:    
    10. Sudha P, Ahsan A, Ashby C, Kausar T, Khera A, Kazeroun MH, Hsu CC, Wang L, Fitzsimons E, Salminen O, Blaney P, Czader M, Williams J, Abu Zaid MI, Ansari-Pour N, Yong KL, van Rhee F, Pierceall WE, Morgan GJ, Flynt E, Gooding S, Abonour R, Ramasamy K, Thakurta A, Walker BA. Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clin Cancer Res. 2022 07 01; 28(13):2854-2864. PMID: 35522533; PMCID: PMC9250632.
      Citations:    
    11. Dimopoulos MA, Schjesvold F, Doronin V, Vinogradova O, Quach H, Leleu X, Montes YG, Ramasamy K, Pompa A, Levin MD, Lee C, Mellqvist UH, Fenk R, Demarquette H, Sati H, Vorog A, Labotka R, Du J, Darif M, Kumar S. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase? 2 trial. Blood Cancer J. 2022 01 24; 12(1):9. PMID: 35075109; PMCID: PMC8786921.
      Citations:    
    12. Djebbari F, Rampotas A, Panitsas F, Lim WY, Lees C, Tsagkaraki I, Gomes AR, Prideaux S, Chen L, Prodger C, Khera A, Gray N, Ellis L, Sangha G, Eyre TA, Moore S, Kothari J, Ramasamy K. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients. PLoS One. 2022; 17(1):e0262388. PMID: 35015781; PMCID: PMC8752006.
      Citations:    
    13. Yong KL, Hinsley S, Auner HW, Bygrave C, Kaiser MF, Ramasamy K, De Tute RM, Sherratt D, Flanagan L, Garg M, Hawkins S, Williams C, Cavenagh J, Rabin NK, Croft J, Morgan G, Davies F, Owen RG, Brown SR. Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive). Haematologica. 2021 10 01; 106(10):2694-2706. PMID: 33910333; PMCID: PMC8485692.
      Citations:    
    14. Ramasamy K, Nooka A, Quach H, Htut M, Popat R, Liedtke M, Tuchman SA, Laubach J, Gasparetto C, Chanan-Khan A, Hertzberg M, deMario M, Nueesch E, Chesne E, Franjkovic I, Lechner K, Kornacker M, Cho HJ. A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood Cancer J. 2021 09 03; 11(9):149. PMID: 34480019; PMCID: PMC8417099.
      Citations:    
    15. Lomas OC, Gooding S, Cabes M, Dreau H, Wilson E, Polzella P, Genomics England Research Consortium, Ramasamy K, Hamblin AD. Validation of clinical-grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly-diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project. EJHaem. 2021 Nov; 2(4):809-812. PMID: 35845211; PMCID: PMC9175844.
      Citations:    
    16. Camilleri M, Cuadrado M, Phillips E, Wilson W, Jenner R, Pang G, Kamora S, Streetly M, Popat R, Bygrave C, Owen R, Cavenagh J, Chapman M, Sive J, Eccersley L, Sheaff M, Benjamin R, Ramasamy K, Cook G, Virchis A, Chavda SJ, Clifton-Hadley L, Scully MA, Yong K. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. Br J Haematol. 2021 05; 193(4):750-760. PMID: 33650100.
      Citations:    
    17. Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, Usmani SZ. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021 02 18; 11(2):40. PMID: 33602913; PMCID: PMC7891472.
      Citations:    
    18. Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. Blood Rev. 2021 09; 49:100808. PMID: 33863601.
      Citations:    
    19. Rampotas A, Djebbari F, Panitsas F, Lees C, Tsagkaraki I, Gomes AR, Prideaux S, Chen L, Prodger C, Khera A, Gray N, Ellis L, Sangha G, Lim WY, Eyre TA, Moore S, Ramasamy K, Kothari J. Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients. Eur J Haematol. 2021 Apr; 106(4):563-573. PMID: 33496996.
      Citations:    
    20. Maouche N, Kishore B, Jenner MW, Boyd K, Bhatti Z, Bird SA, Chander G, Robinson R, Vallance GD, Offer M, Kothari J, Peniket A, Aitchison R, Dungarwalla M, Collings F, Bygrave C, Ramasamy K. Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (=2nd relapse) refractory myeloma: a multicenter real world UK experience. Leuk Lymphoma. 2021 06; 62(6):1396-1404. PMID: 33356703.
      Citations:    
    21. Perrot A, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K, Facon T. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. J Clin Oncol. 2021 01 20; 39(3):227-237. PMID: 33326255; PMCID: PMC8078427.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    22. Cook G, John Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M, Jenner M, Henshaw S, Hall R, Sive J, Stern S, Streetly M, Bygrave C, Soutar R, Rabin N, Jackson GH, United Kingdom Myeloma Forum. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020 07; 190(2):e83-e86. PMID: 32438482; PMCID: PMC7280609.
      Citations:    
    23. Mohty M, Knauf W, Romanus D, Corman S, Verleger K, Kwon Y, Cherepanov D, Cambron-Mellott MJ, Vikis HG, Gonzalez F, Gavini F, Ramasamy K. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom. Eur J Haematol. 2020 Sep; 105(3):308-325. PMID: 32418256; PMCID: PMC7497114.
      Citations:    
    24. Jain A, Ramasamy K. Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis? Clin Lymphoma Myeloma Leuk. 2020 10; 20(10):e769-e776. PMID: 32653456.
      Citations:    
    25. Goldschmidt H, Dimopoulos MA, Rajkumar SV, Weisel KC, Moreau P, Chng WJ, Mikala G, Cavo M, Ramasamy K, Suryanarayan K, Teng Z, Labotka R, Mateos MV. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia. 2020 11; 34(11):3019-3027. PMID: 32327729; PMCID: PMC7584475.
      Citations:    
    26. Jain A, Ramasamy K. Evolving Role of Daratumumab: From Backbencher to Frontline Agent. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):572-587. PMID: 32331971.
      Citations:    
    27. Terpos E, Ramasamy K, Maouche N, Minarik J, Ntanasis-Stathopoulos I, Katodritou E, Jenner MW, Plonkova H, Gavriatopoulou M, Vallance GD, Pika T, Kotsopoulou M, Kothari J, Jelinek T, Kastritis E, Aitchison R, Dimopoulos MA, Zomas A, Hajek R. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Ann Hematol. 2020 May; 99(5):1049-1061. PMID: 32236735.
      Citations:    
    28. Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC, Blad? J. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020 02 13; 10(2):17. PMID: 32054831; PMCID: PMC7018731.
      Citations: 24     Fields:    Translation:Humans
    29. Sharpley FA, Djebbari F, Fourali S, Kothari J, Lynes JA, McLain-Smith S, Ramasamy K. Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma. Leuk Lymphoma. 2020 03; 61(3):732-736. PMID: 31771382.
      Citations:    
    30. Ramasamy K, Dhanasiri S, Thom H, Buchanan V, Robinson S, D'Souza VK, Weisel K. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. Leuk Lymphoma. 2020 03; 61(3):668-679. PMID: 31709875.
      Citations:    
    31. Dimopoulos M, Weisel K, van de Donk NWCJ, Ramasamy K, Gamberi B, Streetly M, Offidani M, Bridoux F, de la Rubia J, Mateos MV, Ardizzoia A, Kueenburg E, Collins S, Di Micco A, Rosettani B, Li Y, Bacon P, Sonneveld P. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. J Clin Oncol. 2018 07 10; 36(20):2035-2043. PMID: 29394124.
      Citations:    
    32. Maciocia N, Melville A, Cheesman S, Sharpley F, Ramasamy K, Streetly M, Jenner M, Benjamin R, Schey S, Maciocia P, Popat R, D'sa S, Rismani A, Cerner A, Yong K, Rabin N. Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. Br J Haematol. 2017 03; 176(6):908-917. PMID: 28211054.
      Citations:    
    33. Gooding S, Lau IJ, Sheikh M, Roberts P, Wong J, Dickens E, Bullement A, Elvidge J, Lee D, Ramasamy K. Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs. PLoS One. 2015; 10(9):e0136207. PMID: 26367874; PMCID: PMC4569348.
      Citations:    
    34. King AJ, Gooding S, Ramasamy K. Managing multiple myeloma in the over 70s: a review. Maturitas. 2015 Feb; 80(2):148-54. PMID: 25541475.
      Citations:    
    35. Lau IJ, Smith D, Aitchison R, Blesing N, Roberts P, Peniket A, Yong K, Rabin N, Ramasamy K. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Ann Hematol. 2015 Apr; 94(4):643-9. PMID: 25345871.
      Citations:    
    36. Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol. 2011 Dec; 155(5):632-4. PMID: 21689088.
      Citations:    
    37. Ramasamy K, Mahmood S, Lim Z, Corderoy S, Devereux S, Mufti GJ, Pagliuca A, Schey S. Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):242-5. PMID: 21575930.
      Citations:    
    38. Schey S, Ramasamy K. Pomalidomide therapy for myeloma. Expert Opin Investig Drugs. 2011 May; 20(5):691-700. PMID: 21413906.
      Citations:    
    39. Schey SA, Morgan GJ, Ramasamy K, Hazel B, Ladon D, Corderoy S, Jenner M, Phekoo K, Boyd K, Davies FE. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol. 2010 Aug; 150(3):326-33. PMID: 20553268.
      Citations:    
    Ramasamy's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (124)
    Explore
    _
    Co-Authors (1)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _